In a filing, Acrivon Therapeutics Inc revealed its 10% Owner PERCEPTIVE ADVISORS LLC unloaded Company’s shares for reported $0.62 million on Apr 30 ’25. In the deal valued at $1.41 per share,437,881 shares were sold. As a result of this transaction, PERCEPTIVE ADVISORS LLC now holds 3,403,025 shares worth roughly $4.02 million.
Then, PERCEPTIVE ADVISORS LLC sold 298,886 shares, generating $400,507 in total proceeds. Upon selling the shares at $1.34, the 10% Owner now owns 3,104,139 shares.
Before that, PERCEPTIVE ADVISORS LLC sold 1,054,669 shares. Acrivon Therapeutics Inc shares valued at $2,056,605 were divested by the 10% Owner at a price of $1.95 per share. As a result of the transaction, PERCEPTIVE ADVISORS LLC now holds 4,306,189 shares, worth roughly $5.08 million.
A number of analysts have revised their coverage, including KeyBanc Capital Markets’s analysts, who began to cover the stock in late January with a ‘”an Overweight”‘ rating. Ladenburg Thalmann also remained covering ACRV and has increased its forecast on September 16, 2024 with a “Buy” recommendation from previously “Neutral” rating. Ladenburg Thalmann revised its rating on April 29, 2024. It rated ACRV as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ACRV
On Monday, Acrivon Therapeutics Inc [NASDAQ:ACRV] saw its stock jump 2.61% to $1.18. Over the last five days, the stock has lost -1.67%. Acrivon Therapeutics Inc shares have fallen nearly -80.40% since the year began. Nevertheless, the stocks have fallen -86.36% over the past one year.
How much short interest is there in Acrivon Therapeutics Inc?
A steep rise in short interest was recorded in Acrivon Therapeutics Inc stocks on 2025-04-30, growing by 0.51 million shares to a total of 1.39 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 0.89 million shares. There was a rise of 36.35%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 01, 2024 when JMP Securities began covering the stock and recommended ‘”a Mkt outperform”‘ rating along with a $14 price target.
